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The ATP-gated P2X1 ion channel is the only P2X sub-
type expressed in human platelets. Via transmission elec-
tron microscopy, we found that P2X1 mediates fast, re-
versible platelet shape change, secretory granule
centralization, and pseudopodia formation. In washed
human platelets, the stable P2X1 agonist ,-methylene
ATP (,-meATP) causes rapid, transient (2–5 s), and dose-
dependent myosin light chain (MLC) phosphorylation, re-
quiring extracellular Ca2. Phosphorylation was inhib-
ited by the calmodulin (CaM) inhibitor W-7, but not by the
Rho kinase inhibitor HA-1077, i.e. it is exclusively regu-
lated by Ca2/CaM-dependent MLC kinase. Correspond-
ingly, the P2X1-induced platelet shape change was inhib-
ited by W-7 and by the MLC kinase inhibitor ML-7 but not
by HA-1077. W-7, ML-7, the protein kinase C inhibitor
GF109203-X, and the Src family kinase inhibitor PP1 in-
hibited the collagen and convulxin-induced early platelet
degranulation, shape change, and subsequent aggrega-
tion, indicating a role for Ca2/CaM and MLC kinase in
these glycoprotein VI-related platelet responses. The se-
creted ATP-mediated P2X1-dependent ERK2 activation
induced by low collagen concentrations contributes to
MLC kinase activation since P2X1 desensitization or
blockade of ERK2 phosphorylation by U0126 strongly at-
tenuated MLC phosphorylation, degranulation, and ag-
gregation. We therefore conclude that at low doses of
collagen, glycoprotein VI activation leads to early protein
kinase C- and MLC kinase-dependent degranulation. Rap-
idly released ATP triggers P2X1-mediated Ca
2 influx, ac-
tivating ERK2, in turn amplifying platelet secretion by
reinforcing the early MLC kinase phosphorylation.
Hence, the P2X1-ERK2-MLC axis contributes to colla-
gen-induced platelet activation by enhancing platelet
degranulation.
P2X receptors are oligomeric non-selective ATP-gated cation
channels expressed in many excitable and non-excitable cells,
where they mediate a variety of physiological processes includ-
ing central and peripheral neurotransmission, smooth muscle
contraction, and hormone secretion (1, 2). Seven P2X receptor
subtypes have been identified so far, but relatively little is
known about the intracellular signaling pathways subserving
their biological actions.
The ATP-gated P2X1 receptor is a rapidly desensitizing, non-
selective cation channel, mediating fast non-selective influx of
Na and Ca2 ions across the cell membrane, resulting in cell
depolarization (3). The direct influx of extracellular Ca2
through this channel rapidly increases intracellular levels and
regulates cellular processes as diverse as muscle contraction,
fertilization, cell proliferation, vesicular function, and apopto-
sis (4). As Ca2 enters the cytosol, it interacts with calmodulin
(CaM).1 Upon Ca2 binding, CaM changes its conformation,
induces dimerization and active site remodeling, and displaces
the auto-inhibitory domains of many different target proteins
(5).
In response to specific agonists, platelets undergo morpho-
logical alterations known as shape change, secrete the con-
tents of their granules, and aggregate (6). These processes
require reorganization of the platelet cytoskeletal structure
and therefore involve Ca2/CaM-regulated pathways. Hence,
phosphorylation of the myosin light chain (MLC) by the Ca2/
CaM-dependent MLC kinase is considered a key step in
platelet activation (7, 8), indicating that platelet actomyosin
is regulated similarly to that found in smooth muscle. Phos-
phorylation of the regulatory light chain subunit of myosin at
serine 19 results in a marked increase of actin-activated
myosin ATPase activity, leading to attachment of myosin to
actin via cross-bridging (9). These events result in the assem-
bly of actin microfilaments, folding of the cell membrane, and
a contractile wave centralizing the platelet secretory
granules.
Rho kinase is also implicated in the regulation of MLC phos-
phorylation (10, 11). Activated by the small GTP-binding pro-
tein RhoA, Rho kinase phosphorylates the myosin-binding sub-
unit of myosin phosphatase and inhibits its activity. Rho
kinase also directly phosphorylates the myosin light chain,
activating myosin in vitro, and induces smooth muscle contrac-
tion in the absence of Ca2. Both the Rho/Rho kinase and
Ca2/CaM-regulated MLC kinase pathways mediate MLC
phosphorylation independently of each other in human plate-
lets (11, 12) as a function of the agonist applied.
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P2X1 is highly expressed in human platelets and megakaryo-
cytes (13, 14); because of the role of Ca2/CaM in platelet MLC
kinase activation, we have presently investigated the P2X1-
mediated Ca2 influx in relation to MLC phosphorylation and
platelet shape change. We have previously shown that the
P2X1-mediated Ca
2 influx triggers phosphorylation of the ex-
tracellular signal-regulated kinase (ERK2), a reaction found to
contribute to platelet activation and secretion induced by low
concentrations of collagen (15, 16). We therefore have also
investigated the relation between MLC kinase and ERK2 acti-
vation during collagen-induced platelet activation, in relation
to P2X1-mediated Ca
2 influx.
Activation of platelets by collagen triggers immediate phos-
pholipase C2-dependent MLC phosphorylation in a Ca2/
CaM-regulated manner, an event instrumental in the early
dense granule release. This degranulation is necessary to com-
plete platelet aggregation via amplification pathways, acti-
vated by released ADP and ATP. We presently found that
released ATP-triggered P2X1 activation results in Ca
2/CaM-
dependent phosphorylation of ERK2, which in turn intensifies
the ongoing activation of MLC kinase. Hence, our work uncov-
ers a central link between ERK2 activation and MLC phospho-
rylation during collagen-induced platelet activation, secretion,
and aggregation.
EXPERIMENTAL PROCEDURES
Materials—The stable, specific P2X1 receptor agonist ,-meATP,
the inositol 1,4,5-trisphosphate receptor antagonist 2-aminoethoxydi-
phenyl borate (2-APB), and the ectonucleotidase apyrase (grade I) were
purchased from Sigma. The ,-meATP was purified by high pressure
liquid chromatography on a Adsorbosphere HS C18, 7-m, 250 
4.6-mm column (Alltech, Bad Segeberg, Germany) (15, 16). Purified
samples, lyophilized and adjusted to pH 7.0 with potassium phosphate
buffer, were kept at 80 °C and were stable over the time interval
studied. The Rho kinase inhibitor HA-1077, the calmodulin inhibitor
W-7, the MLC kinase inhibitor ML-7, and the Src family kinase inhib-
itor PP1 were purchased from Calbiochem. The protein kinase C (PKC)
inhibitor GF109203-X and the MEK1/2 inhibitor U0126 were from
BioMol Research Laboratories (Plymouth Meeting, MA). Collagen (col-
lagen reagent Horm) was from Nycomed (Munich, Germany); the puri-
fied snake venom toxin, convulxin, was obtained through Dr. K. J.
Clementson (Theodor Kocher Institute, University of Berne, Berne,
Switzerland). Hirudin (lepirudin) was from Hoechst, Frankfurt,
Germany.
Preparation of Platelet-rich Plasma, Washed Platelets, and Shape
Change Analyses—Platelet-rich plasma (PRP) was prepared from fresh
blood, taken on acid citrate dextrose (93 mM sodium citrate, 7 mM citric
acid, 0.14 mM dextrose, pH 6.5) as an anticoagulant, supplemented with
1 unit/ml apyrase (grade I), by double centrifugation for 15 min at 150
g. PRP was diluted 3-fold with acid citrate dextrose containing 1 unit/ml
apyrase, and platelets were pelleted at 800  g for 10 min. Washed
platelets were resuspended in Tyrode’s buffer (137 mM NaCl, 12 mM
NaHCO3, 2 mM KCl, 0.34 mM Na2HPO4, 1 mM MgCl2, 5.5 mM glucose,
FIG. 1. P2X1-mediated platelet shape change. Transmission electron microscopy of resting platelets (a) and platelets activated with 2.5 M
,-meATP, fixed 25 s after exposure (b) or 90 s after exposure (c) is shown. The inset shows centralization of platelet granules; other examples
are indicated by arrows. Scale bar is 1 m. Also shown is the time course of MLC phosphorylation (MLC-P) following activation of washed platelets
with 2.5 M ,-meATP, as a function of time, when compared with the total MLC levels indicated in the lower lanes; phospho-MLC and control
MLC (lower panels) antibodies were used. For the shape change studies, arrows represent the moment of agonist application; moments of sampling
for phosphorylation studies and corresponding light transmission tracings and scales are indicated.
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and 5 mM HEPES, pH 7.3) containing 2 units/ml apyrase at a density of
2.5–3.5  105 platelets/l. High concentrations of apyrase were needed
to fully recover P2X1 functionality in the final platelet suspension.
Platelet shape change was detected as a decrease in light transmission
in an ELVI 840 aggregometer with 5-fold amplification of the signal.
CaCl2 (2 mM) was added prior to the recordings; aliquots of washed
platelets were preincubated with the inhibitors as indicated for 1 min
prior to the addition of the agonist. The ADP-induced platelet shape
change was analyzed in the presence of 1.25 g/ml of the IIb3 antag-
onist tirofiban (Merck) to avoid platelet aggregation. In each case, at
least three independent experiments were performed on different
individuals.
Platelet Aggregation and ATP Secretion Analyses—Light transmis-
sion during collagen- or convulxin-induced platelet aggregation was
recorded in apyrase-treated washed platelets with a Chrono-Log Aggre-
gometer. ATP secretion was monitored in washed platelets in parallel
with platelet aggregation by adding firefly luciferase and luciferin and
comparing the luminescence generated by platelet ATP release with an
ATP standard (Chrono-Lume, Kordia, The Netherlands). At least three
independent experiments were performed on platelets from different
individuals.
Electron Microscopy—To preserve physiological Ca2 levels, blood
was taken on hirudin (20 g/ml) and centrifuged at 150  g for 15 min
to yield PRP. Platelet numbers in PRP were diluted to 250,000/l with
autologous platelet-poor plasma. PRP (300 l) was then stirred at 1000
rpm and stimulated with 2.5 M ,-meATP for 25 and 60 s and
immediately fixed at 4 °C in 2.5% glutaraldehyde in 0.1 M phosphate
buffer, at pH 7.2 overnight, after which centrifugation at 800  g for 10
min yielded a condensed platelet pellet. After postfixation in 1% OsO4,
0.1 M phosphate buffer (pH 7.2), and dehydration in graded series of
ethanol, these pellets were embedded in epoxy resin. Ultrathin sections
were cut, stained with uranyl acetate and lead citrate, and examined in
a Zeiss FM 10 electron microscope (Oberkochen, Germany).
Western Blot Detection of Myosin Light Chain and ERK2 Phospho-
rylation—Aliquots of washed platelets (300 l) were incubated in an
aggregometer cuvette with the agonists under stirring at 37 °C. Platelet
activation was stopped by adding 100 l of 4 concentrated SDS sam-
ple buffer at different time points, as indicated. Samples were boiled for
5 min and loaded on a 12% SDS-PAGE gel. After electrophoretic trans-
feral of the proteins to nitrocellulose, membranes were blocked in Tris-
buffered saline-Tween-milk buffer and incubated overnight with the
appropriate primary antibodies: anti-phospho-MLC antibodies (Santa
Cruz Biotechnology, Santa Cruz, CA) or the monoclonal anti-phospho-
p44/42 MAP antibody (New England Biolabs). After adding horseradish
peroxidase-conjugated secondary antibodies, the immunoreactive
bands were visualized by ECL (Amersham Biosciences). For detection of
total proteins, membranes were stripped and reprobed with anti-MLC
and p44/42 antibodies. At least three independent platelet extracts
from different individuals were analyzed.
RESULTS
P2X1 Stimulation Leads to Myosin Light Chain Phosphoryl-
ation—The stable P2X1-specific agonist ,-meATP causes a
fast and dose-dependent, but reversible, platelet shape change
(17, 18). Analysis by transmission electron microscopy of this
transient platelet shape change (Fig. 1, a–c) shows extremely
rapid pseudopodia formation but also illustrates in some plate-
lets a fast and reversible centralization of secretory granules,
in addition to some platelet sphering. These findings indicate
that the ,-meATP-mediated Ca2 influx suffices to cause
functionally relevant morphological changes in platelets, with-
out inducing aggregation or secretion itself. When measured in
FIG. 2. Mechanism of P2X1-mediated platelet shape change. Inhibition of the ,-meATP- and ADP-induced shape change and MLC
phosphorylation (MLC-P) by the specific Rho kinase inhibitor HA-1077 (a), the specific calmodulin antagonist W-7 (b), or the MLC kinase inhibitor
ML-7 (c) is shown. The MLC phosphorylation in stimulated washed platelets is shown for the indicated concentrations of ,-meATP and ADP after
preincubation with the indicated concentrations of inhibitor. Arrows represent the moment of agonist application.
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apyrase-treated washed platelets, ,-meATP also caused a
rapid, transient, and dose-dependent MLC phosphorylation
(Fig. 1, lower right panel). MLC phosphorylation was observed
as early as 2 s and paralleled the actual platelet shape change
response; it was over 30 s after agonist application, i.e. coin-
ciding with the reversibility of the platelet shape change. With
increasing concentrations of ,-meATP, the degree of MLC
phosphorylation paralleled the intensity of the platelet shape
change (not shown).
As was the case for the P2X1-dependent ,-meATP-induced
shape change, no MLC phosphorylation occurred in the ab-
sence of added extracellular CaCl2, and it dropped to very low
levels when apyrase was omitted from the platelet suspension
(not shown), leading to P2X1 desensitization. The inositol 1,4,5-
trisphosphate receptor inhibitor, 2-APB (100 M), did not affect
the P2X1-induced platelet shape change and MLC phosphoryl-
ation (not shown), compatible with an event that relies on the
influx of Ca2 exclusively, without mobilizing calcium from
intracellular stores. In contrast, the ADP-induced MLC phos-
phorylation and shape change, dependent on P2Y1-mediated
Ca2-mobilization, were not inhibited when extracellular Ca2
was omitted, although manifestation of full shape change and
MLC phosphorylation also required apyrase to protect P2Y1
from desensitization (not shown). In agreement with its behav-
ior as a (non-selective) P2 receptor antagonist, suramin abro-
gated the ,-meATP-induced shape change and MLC phos-
phorylation (not shown).
Mechanism of P2X1-mediated MLC Phosphorylation and
Platelet Shape Change—Phosphorylation of the MLC can be
dichotomously regulated by the Ca2 calmodulin-regulated
MLC kinase and by Rho kinase (11); these two pathways can be
activated independently of each other, depending on the type
and concentration of the platelet agonist. We have therefore
investigated the contribution of both kinases to the P2X1-me-
diated MLC phosphorylation by studying ,-meATP-induced
phosphorylation and platelet shape change in the presence of
the specific calmodulin inhibitor W-7 or the Rho kinase inhib-
itor HA-1077. Fig. 2a shows that the ,-meATP-induced plate-
let shape change was not affected by the presence of HA-1077
(20 M); in contrast, the reversible second phase of the ADP-
induced platelet shape change was detectably and repeatedly
reduced at this concentration of HA-1077. Correspondingly,
HA-1077 hardly affected the ,-meATP-induced MLC phos-
phorylation, but strongly reduced the ADP-induced MLC phos-
phorylation, without abolishing it (Fig. 2a). On the other hand,
the ,-meATP-induced shape change was dose-dependently
and completely inhibited by W-7 at 50 M, whereas the ADP-
induced platelet shape change could not be neutralized entirely
at 100 M (Fig. 2b). Correspondingly, the ,-meATP-induced
MLC phosphorylation was eliminated by 50 M W-7, whereas
this concentration only partially inhibited the ADP-induced
MLC phosphorylation (Fig. 2b). The ,-meATP-induced shape
change was also inhibited by the MLC kinase inhibitor ML-7 at
30 M, whereas ML-7 had an effect on the ADP-induced shape
change, comparable with that of W-7. These experiments con-
firm that platelet shape change brought about by P2X1-medi-
ated Ca2 influx does not involve Rho kinase but relies on rapid
and Ca2/CaM-dependent MLC kinase-triggered MLC phos-
phorylation, responsible for rearranging myosin and linked
morphological changes during the transient platelet shape
change reaction.
Ca2/CaM Plays a Central Role in Collagen-induced Platelet
Activation—In view of the role that the P2X1-mediated ERK2
phosphorylation plays in platelet activation by low doses of
collagen (16), we have analyzed whether the P2X1-mediated
Ca2/CaM activation would be involved in this process. We
therefore have reanalyzed the collagen-induced platelet aggre-
gation in the presence of W-7. Fig. 3a shows that at 1 (and 2,
not shown) g/ml collagen, platelet shape change and aggrega-
tion were completely inhibited by W-7, in agreement with older
FIG. 3. Role of Ca2/CaM and MLC kinase in platelet aggregation and degranulation. Aggregation tracings (a) and ATP secretion
profiles (b) following activation of washed platelets, with collagen (1 g/ml), in the absence (upper tracings) or in the presence of the Src family
kinase inhibitor PP1 (20 M), the Ca2/CaM antagonist W-7 (50 M), the MLC kinase inhibitor ML-7 (30 M), or the PKC inhibitor GF109203X
(10 M) are shown.
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findings (19, 20). Parallel recordings of ATP secretion indicated
complete inhibition of degranulation by W-7 (Fig. 3b). Like-
wise, strong inhibition of aggregation, shape change, and ATP
secretion was achieved with ML-7. In agreement with our
previous findings (16), the PKC inhibitor GF109203X also
abrogated these events (Fig. 3). The fact that the Src family
kinase inhibitor PP1 equally prevented platelet aggregation
and ATP secretion almost entirely, confirmed that the colla-
gen-induced platelet activation was the result of GPVI-
mediated platelet activation. Indeed, PP1 is a potent inhibi-
tor of Fyn, a Src family kinase involved in early steps of GPVI
signaling (21, 22). Accordingly, parallel experiments using
the GPVI-selective agonist convulxin, yielded similar results
(not shown). These findings therefore imply that both PKC
and Ca2/CaM-dependent MLC kinase activation are instru-
mental in the early platelet dense granule release induced by
collagen.
During platelet activation by 1 g/ml collagen, the phospho-
rylation of ERK2 depends on ATP-triggered Ca2 influx via
P2X1 (16). We presently found that the ,-meATP-induced
ERK2 phosphorylation was fully inhibited by W-7 (Fig. 4a),
compatible with Ca2/CaM-dependent activation of ERK2. We
therefore expected that, during the collagen-induced platelet
aggregation, W-7, by abrogating both platelet degranulation
and the ATP-mediated P2X1-dependent activation, would pre-
vent ERK2 phosphorylation. Fig. 4b confirms that W-7 largely
prevents the low dose (1 g/ml) collagen-induced phosphoryla-
tion of ERK2. The inhibition by W-7 of ERK2 phosphorylation
induced by higher doses of collagen (2 g/ml), which is inde-
pendent of P2X1, however, suggested the existence of addi-
tional links between Ca2/CaM and ERK2 (see below). Similar
results were found for the convulxin-induced ERK2 phospho-
rylation (not shown).
However, the collagen-induced ERK2 phosphorylation was
entirely eliminated in the presence of PP1, compatible with an
event requiring GPVI-mediated Fyn and Lyn phosphorylation
and subsequent phospholipase C2 activation. These experi-
ments, at a low dose of collagen, confirmed that when the early
secretion of ATP was abrogated, ERK2 phosphorylation was
absent.
P2X1-mediated ERK2 Activation Reinforces MLC Kinase Ac-
tivation—We have previously shown that desensitization of
P2X1 by pretreating the platelets with ,-meATP inhibits low
dose collagen-induced secretion, aggregation, and related
ERK2 phosphorylation (15). Fig. 5a shows that the collagen-
induced MLC phosphorylation is a slow process at low concen-
trations of this agonist but speeds up at higher concentrations.
ML-7 and W-7 abolish MLC phosphorylation elicited by colla-
gen, supportive of a role for Ca2/CaM and MLC kinase in this
event (Fig. 5b). Interestingly, at a low dose of collagen (1
g/ml), MLC phosphorylation can also partially be inhibited by
U0126, at a concentration that prevents ERK2 activation. This
finding uncovers a role for ERK2 in the activation of MLC
kinase. In agreement with a role for P2X1 in this process, MLC
phosphorylation was also strongly reduced by prior P2X1 de-
sensitization using ,-meATP (Fig. 5c). Similarly to our pre-
vious findings on collagen-induced aggregation, at higher col-
lagen concentrations (2 g/ml), neither ,-meATP nor U0126
had any effect on the level of MLC phophorylation. These data
point to a role for P2X1-ERK2-mediated MLC phosphorylation
in platelet secretion and aggregation, elicited by low concen-
trations of collagen.
DISCUSSION
The use of transgenic (23) and knock-out (24) mouse models
recently established a contribution for P2X1 to platelet activa-
tion induced by low concentrations of collagen. These models
have further demonstrated a role for platelet P2X1 in throm-
bosis. Generally, platelet shape change is considered to be the
first measurable response to platelet activation, involving Rho
kinase and MLC kinase (11). It is characterized by spheration,
contraction of the cell, cytoskeletal rearrangement, folding and
ruffling of the surface membrane, and finally, formation of
pseudopodia (25). We therefore have first investigated how
P2X1-mediated Ca
2 influx would activate these enzymes, and
secondly, how these enzymes contribute to P2X1-dependent
pathways of platelet activation.
Collagen leads to rapid platelet activation, accompanied by
protein kinase C-dependent release of nucleotides and subse-
quent P2 receptor activation. Released ATP-mediated P2X1
activation leads to phosphorylation of the mitogen-activated
protein kinase ERK2, thus enhancing platelet activation and
granule release, in a poorly understood manner. We have now
shown that P2X1-activated ERK2 is functionally coupled to
myosin light chain kinase activation and MLC phosphoryla-
tion, important in platelet shape change and degranulation,
reinforcing downstream platelet activation.
The fast reversibility of the P2X1-mediated platelet shape
change has been reported before (16, 17), but transmission
electron microscopy presently showed that platelet shape
change is accompanied by secretory granule centralization.
The specific, non-hydrolysable P2X1 agonist, ,-meATP,
caused rapid, transient, and dose-dependent MLC phospho-
rylation in washed human platelets. These results are con-
sistent with previous reports using saponin-permeabilized
platelets and correlating phosphorylation of myosin and its
interaction with microfilaments responsible for contracting
FIG. 4. Role of Ca2/CaM in ERK2 activation. The figure shows
P2X1-mediated ERK2 phosphorylation in washed platelets activated
with ,-meATP in the absence or presence of W-7, as indicated (a);
collagen-induced ERK2 phosphorylation in the absence or presence of
W-7, as indicated (b); and collagen-induced ERK2 phosphorylation in
the absence or presence of PP1, as indicated (c). Phospho-ERK1/2 MAP
kinase (ERK2-P) and control MAP kinase (ERK2, lower panels) anti-
bodies were used.
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the shell and moving the granules to the center of the platelet
(26, 27). Rho kinase was not involved in the P2X1-induced
shape change and MLC phosphorylation, but the Ca2/CaM
inhibitor W-7 and the MLC kinase inhibitor ML-7 dose-de-
pendently inhibited these phenomena, in agreement with a
direct link between Ca2 influx and MLC phosphorylation.
In general, Ca2/CaM affects cellular growth and stress re-
sponses through ERKs. A number of proximal signaling path-
ways, including G-protein  subunits, PKC, as well as an
increase in intracellular calcium levels, may converge on the
ERK signaling cascade. In vascular smooth muscle, ERK1/2
activation in response to thrombin, angiotensin, or ATP in-
volves both Ca2/CaM and PKC-dependent mechanisms (28–
30). In platelets, we presently found that the P2X1-mediated
ERK2 phosphorylation depends on Ca2/CaM. However, ERK2
is not involved in the rapid P2X1-mediated platelet shape
change since inhibition of ERK2 phosphorylation by U0126 has
no impact on ,-meATP-induced shape change (not shown).
Early studies have indicated that Ca2/CaM-dependent
MLC phosphorylation plays an important role in the platelet
release reaction (19). In view of our earlier finding that P2X1
contributes to the collagen-induced platelet secretion via the
ERK2 pathway, we have studied in more detail the existence of
cross-talk between MLC phosphorylation and ERK2 activation.
The direct analysis of a role for P2X1-dependent Ca
2/CaM
regulation appeared to be complicated because not only was the
collagen-induced platelet aggregation fully inhibited by W-7
and by ML-7, in agreement with earlier findings, but also the
early degranulation (and shape change) was abrogated by
these inhibitors. Yet those findings pointed to the central role
of myosin light chain phosphorylation, even in the early minor
degranulation, in addition to a role for PKC.
Both integrin 21 and GPVI are recognized as major plate-
let receptors underlying interactions with collagen (31, 32). In
its high affinity state, 21 has been proposed to be the major
player in adhesion to collagen. GPVI, non-covalently associated
with the FcR chain, serves as the signal-transducing receptor
in human platelets. Tyrosine phosphorylation of the FcR
chain immunoreceptor tyrosine-based activation motif region
by the Src family kinases Lyn and Fyn activates Syk and LAT,
initiating enzyme cascades involving phosphatidylinositol 3-ki-
nase and phospholipase C2. Upon its phosphorylation, PLC2
migrates to the plasma membrane, where it generates inositol
1,4,5-trisphosphate and 1,2-diacylglycerol. Finally, these
events result in intracellular calcium mobilization, shape
change, activation of PKC, and inside-out signaling, resulting
in expression of IIb3-binding sites. We have presently con-
firmed that the P2X1-mediated amplification reactions during
the collagen-induced activation of platelets are the result of
GPVI-mediated signaling, leading to early degranulation, in
turn responsible for further nucleotide-dependent platelet ac-
tivation. Indeed, the early degranulation and subsequent plate-
let aggregation were completely abrogated by the Src family
kinase inhibitor PP1, as well as by W-7 and ML-7, illustrating
that they depend on PLC2 activation, subsequent Ca2-mobi-
lization, PKC activation, and Ca2/CaM-dependent MLC phos-
phorylation. Released ADP then triggers further Ca2-mobili-
zation after activation of PLC.
We presently found that the weak MLC phosphorylation
accompanying early collagen-induced platelet degranulation is
up-regulated by ERK2. The finding that desensitization of
P2X1 either by prior ,-meATP or by U0126 both strongly
reduce the amplification of MLC phosphorylation provides a
mechanistic basis for the role of P2X1 in activating both en-
zymes, as illustrated in Fig. 6. Thus, released ATP contributes
via P2X1 to the collagen-mediated activation of platelets be-
cause it amplifies MLC phosphorylation. ERK2, activated by
the P2X1-mediated Ca
2 influx, by phosphorylating MLC ki-
nase would accelerate MLC phosphorylation, and ultimately,
platelet activation. Accordingly, in other cell types, MLC ki-
nase activity was shown to be regulated by MAP kinase-de-
pendent phosphorylation in functional assays; for example, the
FIG. 5. P2X1-mediated ERK2 phos-
phorylation enhances MLC kinase
activation. This figure shows the kinet-
ics of MLC phosphorylation at the indi-
cated concentrations of collagen (a); inhi-
bition of MLC phosphorylation by the
Ca2/CaM inhibitor W-7 and the MLC ki-
nase inhibitor ML-7, at the indicated con-
centration of collagen (b); and inhibition
of MLC phosphorylation after P2X1 de-
sensitization (with ,-meATP added si-
multaneously to collagen, see Ref. 16) and
by the MAPK kinase inhibitor U0126, at
the indicated concentrations of collagen
(c). Phospho-MLC (P-MLC) and control
MLC (lower panels) antibodies were used.
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functional interaction between MAP kinase and MLC kinase
has been implicated in carcinoma cell migration (33). Several
molecular interactions depend on calmodulin; therefore, the
pharmacological action of W-7 on ERK2 phosphorylation by
,-meATP does not necessarily rely on a single mechanism,
explaining the dashed arrow in Fig. 6. Indeed, we have shown
before that ERK2 phosphorylation is also a PKC-dependent
process (16). Fig. 6 highlights the role in platelets of secreted
ATP. It is evident that released ADP will also stimulate MLC
phosphorylation, following Ca2-mobilization, in agreement
with the role of MLC kinase in the ADP-induced platelet shape
change (Fig. 2). In conclusion, the present work shows that
P2X1 activation by ATP leads to both activation of MLC kinase
and of ERK2 and that the highly regulated interaction between
both enzymes contributes to collagen-mediated platelet
aggregation.
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FIG. 6. Diagram of the P2X1-triggered signaling reactions dur-
ing collagen-induced platelet activation. At low concentrations of
collagen, GPVI-collagen interactions trigger PLC2 activation, leading
to PKC activation, Ca2-mobilization, and Ca2-calmodulin-dependent
activation of MLC kinase (MLCK), both enzymes contributing to minor
early platelet degranulation. Released ATP causes P2X1-mediated Ca
2
influx, leading to progressive Ca2/CaM-dependent ERK2 phosphoryl-
ation. The collagen-induced Ca2/CaM-mediated phosphorylation of
MLC is strongly enhanced by the activated ERK2 through phosphoryl-
ation dependent amplification of MLC kinase activation. The resulting
up-regulated MLC phosphorylation (P-MLC) then contributes to fur-
ther platelet degranulation, completing platelet aggregation.
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